



**HAL**  
open science

## Exploring the basic mechanisms in Cystic Fibrosis: Promoting data presentation and discussion at the 16th ECFS Basic Science Conference

Isabelle Callebaut, Martin Mense, Carlos M. Farinha

### ► To cite this version:

Isabelle Callebaut, Martin Mense, Carlos M. Farinha. Exploring the basic mechanisms in Cystic Fibrosis: Promoting data presentation and discussion at the 16th ECFS Basic Science Conference. Journal of Cystic Fibrosis, 2020, 19 (S1), pp.S1-S4. 10.1016/j.jcf.2019.12.013 . hal-03030402

**HAL Id: hal-03030402**

**<https://hal.sorbonne-universite.fr/hal-03030402v1>**

Submitted on 30 Nov 2020

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

**Exploring the basic mechanisms in Cystic Fibrosis: promoting data presentation and discussion at the 16th EFCS Basic Science Conference**

**Isabelle Callebaut<sup>1</sup>, Martin Mense<sup>2</sup>, Carlos M. Farinha<sup>3</sup>**

1. Sorbonne Université, Muséum National d'Histoire Naturelle, UMR CNRS 7590, Institut de Minéralogie, de Physique des Matériaux et de Cosmochimie, IMPMC, 75005 Paris, France

2. Cystic Fibrosis Foundation, CFFT Lab, 44 Hartwell Ave., Lexington, MA 02421, USA

3. Biosystems and Integrative Sciences Institute, Faculty of Sciences, University of Lisboa, Campo Grande 1749-016, Lisboa, Portugal

The revolution in cystic fibrosis treatment is rooted in tremendous interdisciplinary research efforts, which led in recent years to significant progress in precision medicine. Since 2004, a key annual event for the CF research community is the ECFS Basic Science Conference (BSC), which is an ideal venue for deep discussions around topical subjects and fosters basic CF-related research in Europe and beyond. This special issue explores topics that were featured at the 16th ECFS BSC, held in Dubrovnik in March 2019 and provides an overview of recent progress in various fields for understanding disease mechanisms, developing relevant cell and animal models and designing breakthrough therapies. The special issue also identifies a number of the key issues and challenges in the future development of transformative therapies for all patients with CF.

## **1. Background**

Thirty years ago, the identification and sequencing of the *CFTR* gene enabled the unraveling of the pathogenesis of cystic fibrosis and has paved the way for targeting the root cause of the disease [1-3]. This has stimulated tremendous interdisciplinary research efforts, which has led in recent years to significant progress in CF precision medicine. These efforts have improved our basic understanding in several branches of biology, going far beyond *CFTR*, with results from this community paving the way in other pathologies. In the CF research community, various disciplines come together, including genetics, physiology, biochemistry, molecular biology, biophysics, immunology, microbiology and pharmacology. The ECFS Basic Science Conference (BSC), which has been held every year since 2004, constitutes a key event for the CF research community, allowing deep discussions around topical subjects and fostering basic CF-related research in Europe and beyond. Despite enormous progress, important challenges remain, and the BSC is a perfect venue to identify critical issues and facilitate collaborations, especially through informal discussions between senior investigators and young scientists.

Two years ago, a first Special Issue of the Journal of Cystic Fibrosis Basic Science Supplement allowed CF science research, discussed at the 14th ECFS Basic Science Conference, held in Albufeira, Portugal, 29 March to 1 April 2017, accessible to the broader CF community and beyond. This issue gathered articles authored by renowned experts in the field, providing summaries on the core content of the conference and on recent highlights and

breakthroughs in basic and translational CF research. Given the interest raised by this initiative, a second special issue has been prepared for disseminating topical issues presented at the 16th ECFS Basic Science Conference, held in Dubrovnik, Croatia, 27 to 30 March 2019. The program of this conference, in line with the previous ones, was based on single session symposia, covering multiple aspects of CF research and two keynote lectures opening and closing the event. A pre-conference seminar, organized by European CF patient organizations and chaired by Bertrand Kleizen and David N. Sheppard, was devoted to a discussion around the new insights gained on the CFTR structure and function and implications for the development of modulators (ref the output). The articles included in this special issue are intended to give a succinct summary of the core content of the conference and to identify potential avenues on key issues and challenges to further develop transformative therapies for all patients with CF.

## **2. CFTR: from genetics to structure, function, regulation and modulation**

The development of CFTR modulators, culminating with the latest promising data of triple combination therapies (TCTs) [4-6] (which led to its approval by the FDA and the submission of a Marketing Approval Application to the EMA), has significantly changed the landscape for CF treatment. It became clear from data gathered from recent studies that most of the pathogenic CFTR variants confer numerous and complex abnormalities, highlighting the need to view CF precision therapeutics from an updated perspective [7, 8]. In return, it has also been observed that modulators may have an effect on a broad range of variants and disease subcategories. Hence, it is now obvious that the vast majority of patients with CF should benefit from modulator therapy, combining drugs with different activities and targeting different sites, probably acting via allosteric interaction [9].

The article by [Cutting and Sharma](#) [10] traces the rich history of genetics and genomics applied to CF since the discovery of the *CFTR* gene thirty years ago and describes the efforts made via extensive studies to link the consequences of the numerous variants (missense, non-sense, frame shift, canonical splice site) on disease susceptibility, including evaluation of CFTR function and response to modulators. Among others, it highlights that even minor improvements in CFTR function for patients with severe CF disease may lead to significant clinical changes. This review also reports on new perspectives, generated using genomic

approaches, to evaluate the effect of genetic and environmental modifiers as determinants of phenotype variability. In line with this review, two other articles by [Paranjapye and colleagues](#) [11] and by [Chevalier and Hinzpeter](#) [12] illustrate how genetic variations within and outside the *CFTR* locus, revealed by the use of cutting-edge techniques of functional genomics, contribute to the variability of the disease severity. These involve *cis*-regulatory elements acting on the gene transcription level, various modifier genes, as well as complex alleles, defined by the presence of at least two variations on the same *CFTR* allele. These studies have the potential to result in the development of specific diagnostic tools and personalized therapies, as well as to aid the identification of novel therapeutic targets.

Challenges remain in the therapeutic area, especially as *i)* *CFTR* modulators are not available for all *CFTR* mutations; and *ii)* modulators with greater efficacy are required to prevent disease progression. The success of the most recently evaluated Vertex drug, Trikafta, may go some way towards the goal of disease prevention, at least when people with CF are treated from a young age, but data about the long-term benefits and consequences are not yet available. Understanding the molecular basis of the impact of mutations and modulators on *CFTR* folding, structure and function will provide the foundation on which more efficient or alternative therapeutic approaches may be built.

A first article by [Kleizen and colleagues](#) [13] features the discussions held at the Pre-Conference Seminar, which was organized by the national patients organizations. It describes how combined efforts from structural biology and electrophysiology may allow better understanding of *CFTR*'s structure-function relationships and the impact of disease-causing mutations and drugs. This field of research has unquestionably benefited from the formidable advances offered by cryo-electron microscopy, which recently suggested a potential binding site for ivacaftor [14]. However, work is still needed to cover the full, dynamical conformational landscape of the *CFTR* protein at the atomic resolution level, particularly regarding the different conformations of the active WT *CFTR* protein and of mutated proteins as well as addressing the comprehensive mapping of modulator-binding sites and modulator mechanisms of action.

A second article by [Bose and colleagues](#) [15] highlights the potential of single-molecule studies in understanding the effect of mutations and modulators on NBD1 co-translational

folding as well as on the folding of transmembrane helical hairpins. These fundamental investigations of the folding mechanisms (also see [16, 17] for recent articles published in the field) and of CFTR thermodynamics stability (also see [18] for a recent advance in the field) might lead to important mechanism-based therapeutic avenues targeting CFTR and other folding disorders. This review also clearly indicates how high-resolution single-channel recording on CFTR from different species provides insightful information to help understand critical sequence-structure-function relationships, with practical outcomes on the suitability of CF animal models for pharmacological studies using CFTR modulators. Finally, the article also sheds light on the emergence of co-potentiators, acting synergistically and restoring therapeutically relevant levels of activity to rare CF mutations.

CFTR belongs to a wide, dynamic network of interactions, called the CFTR functional landscape or CFTR social network, intervening on the synthesis, folding, stability, trafficking and function of the protein. The article by [Amaral and colleagues](#) [19], describes how genetic variations impact on the ability of CFTR to interact with this network and how this network can be modulated to rescue the defects associated with the most frequent F508del CFTR variant. Focus on this CFTR “regulome” will generate novel important insights which will facilitate identification of novel therapeutic targets. This will be of particular relevance to patients carrying CFTR genotypes that are not responsive to CFTR-directed approaches [20], and deepen our understanding of how these interactions shape CFTR fate in the cell [21, 22].

### **3. Beyond CFTR: the epithelial channelome**

In addition to CFTR, focus has been given to other ion channels – including the epithelial Na<sup>+</sup> channel (ENaC), Cl<sup>-</sup> channels TMEM16A and SLC26A9 as well as the H<sup>+</sup>/K<sup>+</sup>-ATPase ATP12A – as they can be considered as alternative targets. Such channels may be the targets of CFTR mutation-agnostic therapeutic strategies, and potentially compensate for CFTR dysfunction by improving surface hydration and pH regulation in the airways. Numerous abstracts related to the study of these actors of the epithelial channelome were presented at the conference, either at the level of a dedicated symposium, in the poster sessions or within the ECFS Basic Science Working group chaired by Margarida Amaral and Jeff Beekman. The article by [Quesada and Dutzler](#) [23] summarizes the current knowledge acquired on the

structure-function relationships of the chloride channels TMEM16A and SLC26A9, as well as synthetic anionophores, which can form lipid-soluble complexes allowing chloride and bicarbonate shuttling across membranes. The interest in such molecules as part of a therapeutic strategy in CF was recently supported by the demonstration that amphotericin, an antifungal medication that forms non-selective ion-passing pores, restores ion transport and antibacterial defenses when tested *in vitro* and in an *in vivo* animal model of the disease [24, 25].

#### **4. The airway epithelium and CF model systems**

Lung pathology progression and disease severity in CF is linked to pathological remodeling of the airway epithelium. The article by [Barbry and colleagues](#) [26] gives an overview of the current knowledge on the mechanisms regulating airway epithelial cell regeneration and repair, which is a multi-step process leading to the redifferentiation of progenitor cells into all cell types contributing to the function of the normal epithelia. The article especially focuses on pulmonary ionocytes and deuterosomal cells, two recently described airway cell types identified by powerful single-cell RNA-sequencing techniques and suggested to have great relevance for CF [27-29]. The authors list an ensemble of future directions that need to be explored in order to specify the role of these cells and others in the homeostasis of normal and CF airway epithelium. They highlight the importance of the “omics” approach in understanding the mechanisms of airway epithelial repair in an integrative way.

Many efforts have been undertaken in the CF field to generate animal models lacking functional CFTR, yielding information on the mechanisms of pathogenesis, with organ-specific differences to the human CF phenotype [30]. Representative libraries of patient-specific epithelial cell models are developed for disease modeling, preclinical testing of drug response, and biobanking for future drug discovery. Cell models can be derived from embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs) and tissue-resident stem cells ASCs (Adult Stem Cells). While the different models, detailed in several recent reviews (e.g. [31, 32]) have been discussed at the conference, the article by [de Poel and colleagues](#) [33] focuses on the interest of ASC-based intestinal organoids, used in the Dutch Rainbow and European HIT-CF projects, enabling CF disease classification, drug development and

personalized treatment optimization, considering the clinical heterogeneity among CF patients.

## **5. Genetic therapies for CF**

While genetic therapies have faced challenges associated with gene delivery and expression persistence of CFTR over time, related to mucociliary barriers in the CF airways, novel technologies have generated new ways to address these issues [34, 35]. There are numerous approaches in development, which were widely debated at the conference, in particular related to CFTR mRNA therapy and CRISPR gene editing, with the possibility of editing epithelial progenitor cells. The article by [Boyd and colleagues](#) [36] more specifically focuses on the potential of ENaC siRNA targeting and antisense oligonucleotide approaches to CF therapy, as well as those offered by plasmid-mediated therapies using viral or non-viral liposomal vectors, with initial data highlighting a favorable effect of gene therapy on the modulation of lung function. Questions remain relative to the challenges of delivery and to the cell-types which have to be targeted in the epithelium for such genetic therapies, given that the airway epithelium contains high and low-CFTR expressing cells, each playing distinct roles in the physiology and protection from infection [26, 37].

## **6. Host-microbe and microbe-microbe interactions in CF**

In 2018, the ECFS Basic Science pre-conference symposium focused on the lung and gut microbiome and the clinical implications for CF from data generated by new and innovative technologies, and the question was raised how to standardize operating procedures and guidelines for microbiome analysis [38]. In this issue, the article by [Armbruster and colleagues](#) [39] – summarizing the dedicated symposium of the 2019 BSC – brings an interesting perspective on how the host nutritional environment influences microbial pathogenesis and feeds back into host-microbe and microbe-microbe interactions, how these intervene on antimicrobial susceptibility of bacterial biofilms, and how the immune response may drive changes in microbiota composition.

## **7. Concluding remarks**



Recent advances in basic and translational CF research have been described in the concise review articles presented in this special issue related to the 16<sup>th</sup> ECFS Basic Science Conference. Other topics also warrant mention including mucociliary transport (MCT) and mucociliary clearance (MCC) and the key role that mucus and mucins play in airways defense [40]. This topic was addressed at the Conference through the presentation by Michael Welsh, who described the *in vivo* imaging assay of MCT in newborn pigs [41]. Another topic related to mucus obstruction is that of the chronic, non-resolving inflammation, which remains a key issue for lung disease severity and progression in CF patients [42, 43]. Finally, the reviews presented here essentially focus on novel results, directions and challenges remaining in the CF field. However, remarkable improvements in health outcomes for people with CF, especially the recent development of CFTR modulator triple drug combinations, have been made possible by a highly committed and interdisciplinary CF research community.

### **Acknowledgements**

We thank the speakers of the 16th ECFS Basic Science Conference for their excellent contributions and the ECFS for supporting this special issue, and we are grateful to Cliff Taggart for his help in its preparation. The work in the Editorial Summary's authors laboratories was supported in part by grants from the French Association Vaincre La Mucoviscidose and HPC resources from GENCI-[CINES] (to IC), UID/MULTI/04046/2019 Research Unit grant (from Fundação para a Ciência e a Tecnologia, Portugal) to BioISI and award FARINH1910 from the Cystic Fibrosis Foundation (to CMF). MM is a Cystic Fibrosis Foundation employee and the work at the CFFT Lab is entirely funded by the CF Foundation.

### **Conflict of interest**

IC, CMF, and MM have no relevant conflicts of interest related to this work.

### **Author contributions**

IC drafted the summary. All authors revised it critically for important intellectual content and approved the final version of the summary.

## References

- [1] Kerem B, Rommens JM, Buchanan JA, Markiewicz D, Cox T, Chakravarti A, et al. Identification of the cystic fibrosis gene: genetic analysis. *Science*. 1989;245:1073-80.
- [2] Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. *Science*. 1989 245:1066-73.
- [3] Rommens JM, Iannuzzi MC, Kerem B, Drumm ML, Melmer G, Dean M, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. *Science*. 1989;245:1059-65.
- [4] Davies J, Moskowitz SM, Brown C, Horsley A, Mall MA, McKone EF, et al. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. *N Engl J Med*. 2018;379:1599-611.
- [5] Keating D, Marigowda G, Burr L, Daines C, Mall MA, McKone EF, et al. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. *N Engl J Med*. 2018;379:1612-20.
- [6] Middleton PG, Mall MA, Dřevínek P, Lands LC, McKone EF, Polinemi D, et al. Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. *N Engl J Med*. 2019;381:1809-19.
- [7] Veit G, Avramescu RG, Chiang AN, Houck SA, Cai Z, Peters KW, et al. From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations. *Mol Biol Cell*. 2016;27:424-33.
- [8] Joshi D, Ehrhardt A, Hiong JS, Sorscher E. Cystic fibrosis precision therapeutics: emerging considerations. *Pediatric Pulmonology*. 2019;54:S13-S7.
- [9] Veit G, Xu H, Dreano E, Avramescu RG, Bagdany M, Beitel LK, et al. Structure-guided combination therapy to potently improve the function of mutant CFTRs. *Nat Med*. 2018;24:1732-42.
- [10] Cutting G, Sharma N. The genetics and genomics of Cystic Fibrosis. *J Cyst Fibr*. 2019.
- [11] Paranjapye A, Ruffin M, Harris A, Corvol H. Genetic variation in CFTR and modifier loci may modulate cystic fibrosis disease severity. *J Cyst Fibr*. 2019.
- [12] Chevalier B, Hinzpeter A. The influence of CFTR complex alleles on precision therapy of cystic fibrosis. *J Cyst Fibr*. 2019.
- [13] Kleizen B, Hunt JF, Callebaut I, Hwang T-C, Sermet-Gaudelus I, Hafkemeyer S, et al. CFTR: New insights into structure and function and implications for modulation by small molecules. *J Cyst Fibr*. 2019.
- [14] Liu F, Zhang Z, Levit A, Levring J, Touhara KK, Shoichet BK, et al. Structural identification of a hotspot on CFTR for potentiation. *Science*. 2019;364:1184-8.
- [15] Bose SJ, Krainer G, Ng DR, Schenkel M, Shishido H, Yoon JS, et al. Towards next generation therapies for cystic fibrosis: folding, function and pharmacology of CFTR. *J Cyst Fibros*. 2019.
- [16] Oliver KE, Rauscher R, Mijnders M, Wang W, Wolpert MJ, Maya J, et al. Slowing ribosome velocity restores folding and function of mutant CFTR. *J Clin Invest*. 2019;in press.
- [17] van Willigen M, Vonk AM, Yeoh HY, Kruisselbrink E, Kleizen B, van der Ent CK, et al. Folding-function relationship of the most common cystic fibrosis-causing CFTR conductance mutants. *Life Sci Alliance*. 2019;2:e201800172.

- [18] Sigoillot M, Overtus M, Grodecka M, Scholl D, Garcia-Pino A, Laeremans T, et al. Domain-interface dynamics of CFTR revealed by stabilizing nanobodies. *Nat Commun.* 2019;10:2636.
- [19] Amaral MD, Hutt DM, Tomati V, Botelho HM, Pedemonte N. CFTR processing, trafficking and interactions. *J Cyst Fibr.* 2019.
- [20] Loureiro CA, Santos JD, Matos AM, Jordan P, Matos P, Farinha CM, et al. Network Biology Identifies Novel Regulators of CFTR Trafficking and Membrane Stability. *Front Pharmacol.* 2019;10:619.
- [21] Santos JD, Canato S, Carvalho AS, Botelho HM, Aloria K, Amaral MD, et al. Folding Status Is Determinant over Traffic-Competence in Defining CFTR Interactors in the Endoplasmic Reticulum. *Cells.* 2019;8:pii: E353.
- [22] Canato S, Santos JD, Carvalho AS, Aloria K, Amaral MD, R M, et al. Proteomic interaction profiling reveals KIFC1 as a factor involved in early targeting of F508del-CFTR to degradation. *Cell Mol Life Sci.* 2018;75:4495-509.
- [23] Quesada R, Dutzler R. Alternative chloride transport pathways as pharmacological targets for the treatment of cystic fibrosis. *J Cyst Fibr.* 2019.
- [24] Sheppard DN, Davis AP. Fighting cystic fibrosis with small molecules. *Nature.* 2019;567:315-7.
- [25] Muraglia KA, Chorghade RS, Kim, BR, Tang X, Shah V, Grillo A, et al. Small-molecule ion channels increase host defences in cystic fibrosis airway epithelia. *Nature.* 2019;567:405-8.
- [26] Barbry P, Cavard A, Chanson M, Jaffe AB, Plasschaert LW. Regeneration of airway epithelial cells to study rare cell states in cystic fibrosis. *J Cyst Fibr.* 2019.
- [27] Montoro DT, Haber AL, Biton M, Vinarsky V, Lin B, Birket SE, et al. A revised airway epithelial hierarchy includes CFTR-expressing ionocytes. *Nature.* 560:319-24.
- [28] Plasschaert LW, Žilionis R, Choo-Wing R, Savova V, Knehr J, Roma G, et al. A single-cell atlas of the airway epithelium reveals the CFTR-rich pulmonary ionocyte. *Nature.* 2018;560:377-81.
- [29] Revinski DR, Zaragosi LE, Boutin C, Ruiz-Garcia S, Deprez M, Thomé V, et al. CDC20B is required for deuterosome-mediated centriole production in multiciliated cells. *Nat Commun.* 2018;9:4668.
- [30] Rosen BH, Chanson M, Gawenis LR, Liu J, Sofoluwe A, Zoso A, et al. Animal and model systems for studying cystic fibrosis. *J Cyst Fibr.* 2018;17:S28-S34.
- [31] Atawade NT, Wong SL, Hewson CK, Fawcett LK, Kicic A, Jaffe A, et al. Human primary epithelial cell models: promising tools in the era of Cystic Fibrosis personalized medicine. *Front Pharmacol.* 2019;9:149.
- [32] Clancy JP, Cotton CU, Donaldson SH, Solomon GM, VanDevanter DR, Boyle MP, et al. CFTR modulator theratyping: Current status, gaps and future directions. *J Cyst Fibros.* 2019;18:22-34.
- [33] de Poel E, Lefferts JW, Beekman JM. Intestinal organoids for Cystic Fibrosis research. *J Cyst Fibr.* 2019.
- [34] Hart SL, Harrison P. Genetic therapies for cystic fibrosis lung disease. *Curr Opin Pharmacol.* 2017;34:119-24.
- [35] Yan Z, McCray PJ, Engelhardt JF. Advances in gene therapy for cystic fibrosis lung disease. *Hum Mol Genet.* 2019;28(R1):R88-R94.
- [36] Boyd C, Guo S, Huang L, Kerem B, Oren YS, Walker AJ, et al. New approaches to genetic therapies for Cystic Fibrosis. *J Cyst Fibr.* 2019.

- [37] Engelhardt JF, Yankaskas JR, Ernst SA, Yang Y, Marino CR, Boucher RC, et al. Submucosal glands are the predominant site of CFTR expression in the human bronchus. *Nat Genet.* 1992;2:240-8.
- [38] Héry-Arnaud G, Boutin S, Cuthbertson L, Elborn SJ, Tunney MM. The lung and gut microbiome: what has to be taken into consideration for cystic fibrosis? *J Cyst Fibr.* 2019;18:13-21.
- [39] Armbruster CR, Coeyne T, Touqui L, Bomberger JM. Interplay between host-microbe and microbe-microbe interactions in cystic fibrosis. *J Cyst Fibr.* 2019.
- [40] Morrison CB, Markovetz MR, Ehre C. Mucus, mucins, and cystic fibrosis. *Pediatr Pulmonol.* 2019;54 (Suppl 3):S84-S96.
- [41] Fischer AJ, Pino-Argumedo MI, Hilkin BM, Shanrock CR, Gansemer ND, Chaly AL, et al. Mucus strands from submucosal glands initiate mucociliary transport of large particles. *JCI Insight.* 2019;10:124863.
- [42] McElvaney OJ, Wade P, Murphy M, Reeves EP, McElvaney NG. Targeting airway inflammation in cystic fibrosis. *Expert Rev Respir Med.* 2019;13:1041-55.
- [43] Mall MA, Danahay H, Boucher RC. Emerging Concepts and Therapies for Mucoobstructive Lung Disease. *Ann Am Thorac Soc.* 2018;15(Suppl 3):S216-S26.